Literature DB >> 11388971

Two-year follow-up after a randomised controlled trial of self- and clinician-accompanied exposure for phobia/panic disorders.

J M Park1, D Mataix-Cols, I M Marks, T Ngamthipwatthana, M Marks, R Araya, T Al-Kubaisy.   

Abstract

BACKGROUND: Long-term follow-up has rarely been reported after self-exposure therapy for phobias. AIMS: Completion of such a follow-up.
METHOD: Two-year follow-up was achieved in 68 (85%) of 80 patients with phobias who had completed a previous 14-week randomised controlled trial comparing therapist-accompanied self-exposure, self-exposure or self-relaxation. Measures were self-reported ratings of symptoms, satisfaction and use of other treatment.
RESULTS: Improvement at week 14 was maintained 2 years later. Clinician-accompanied exposure and self-exposure did not differ on any measure. Compliance with self-exposure homework during weeks 0-8 predicted more improvement 2 years later. Patients who failed to improve with relaxation by week 14 improved after subsequent crossover to exposure. A need for more treatment for their phobias was still felt by 33 patients (49%).
CONCLUSIONS: Patients with phobias maintained their improvement to 2-year follow-up after the end of self-exposure therapy.

Entities:  

Mesh:

Year:  2001        PMID: 11388971     DOI: 10.1192/bjp.178.6.543

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  2 in total

Review 1.  Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis.

Authors:  Alessandro Pompoli; Toshi A Furukawa; Hissei Imai; Aran Tajika; Orestis Efthimiou; Georgia Salanti
Journal:  Cochrane Database Syst Rev       Date:  2016-04-13

2.  Three year naturalistic outcome study of panic disorder patients treated with paroxetine.

Authors:  Pinhas N Dannon; Iulian Iancu; Ami Cohen; Katherine Lowengrub; Leon Grunhaus; Moshe Kotler
Journal:  BMC Psychiatry       Date:  2004-06-11       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.